Viatris (VTRS) News Today $9.24 +0.34 (+3.82%) Closing price 04:00 PM EasternExtended Trading$9.13 -0.11 (-1.19%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Viatris Inc.: Viatris Provides Update on Phase 3 Study of MR-139 for BlepharitisJuly 18, 2025 | finanznachrichten.deWhy Viatris (VTRS) Stock Is Falling TodayJuly 18, 2025 | msn.comViatris Hits Snag In Eye Drug Study—Phase 3 Plans Under ReviewJuly 18, 2025 | benzinga.comViatris eye ointment fails late-stage study for eye condition, shares fallJuly 18, 2025 | msn.comViatris eye ointment fails late-stage study, shares fallJuly 18, 2025 | reuters.comViatris down on late-stage trial setback for eye disorder therapyJuly 18, 2025 | msn.comViatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study GoalJuly 18, 2025 | msn.comViatris Stock Tumbles as Eyelid Inflammation Treatment Misses TargetJuly 18, 2025 | barrons.comViatris eye therapy fails to meet late-stage trial goalJuly 18, 2025 | reuters.comViatris Provides Update on Phase 3 Study of MR-139 for BlepharitisJuly 18, 2025 | prnewswire.comViatris (VTRS) Announces Positive Top-line Results from VEGA-3July 17, 2025 | finance.yahoo.comViatris: A Contrarian Bet With Virtually No DownsideJuly 16, 2025 | seekingalpha.comViatris Certified as a Great Place to Work® in CanadaJuly 15, 2025 | finance.yahoo.com13 Best Low Priced Pharma Stocks to Buy NowJuly 15, 2025 | insidermonkey.comViatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharmaJuly 15, 2025 | finance.yahoo.comGoldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PTJuly 11, 2025 | insidermonkey.comJ&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drugJuly 9, 2025 | msn.comThe 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings CallJune 27, 2025 | msn.comViatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in PresbyopiaJune 26, 2025 | finanznachrichten.deTheravance higher as China approves Viatris-partnered COPD therapyJune 26, 2025 | msn.comViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in PresbyopiaJune 26, 2025 | prnewswire.comViatris: The Problem With The Business ModelJune 25, 2025 | seekingalpha.com3 Reasons to Avoid VTRS and 1 Stock to Buy InsteadJune 17, 2025 | msn.comViatris to Report Second Quarter 2025 Financial Results on August 7, 2025June 12, 2025 | prnewswire.comKuehn Law Encourages Investors of Viatris Inc. to Contact Law FirmJune 10, 2025 | globenewswire.comVTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost ReviewJune 10, 2025 | msn.comViatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptJune 9, 2025 | seekingalpha.comGoldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral RecommendationJune 7, 2025 | msn.comViatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection FalloutJune 6, 2025 | insidermonkey.comViatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference TranscriptJune 5, 2025 | seekingalpha.comViatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their RightsJune 3, 2025 | businesswire.comDEADLINE ALERT for VTRS and CGC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 3, 2025 | globenewswire.comVTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 2, 2025 | globenewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ViatrisJune 2, 2025 | globenewswire.comViatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRSJune 2, 2025 | globenewswire.comVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 2, 2025 | prnewswire.comDEADLINE TOMORROW: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Inquire About a Securities Fraud Class Action by June 3, 2025June 2, 2025 | prnewswire.comVTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris Inc.? BFA Law Notifies Investors of Imminent June 3 Securities Class Action Deadline (NASDAQ:VTRS)June 2, 2025 | globenewswire.comViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2, 2025 | prnewswire.comLost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & KorsinskyJune 1, 2025 | markets.businessinsider.comVTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRSJune 1, 2025 | globenewswire.comViatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud LawsuitJune 1, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRSJune 1, 2025 | prnewswire.comVTRS DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action...May 31, 2025 | markets.businessinsider.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ViatrisMay 31, 2025 | prnewswire.comVTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)May 31, 2025 | globenewswire.comDeadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMay 30, 2025 | businesswire.comViatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – VTRSMay 30, 2025 | globenewswire.comSHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 DeadlineMay 30, 2025 | globenewswire.com Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address VTRS Media Mentions By Week VTRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.000.59▲Average Medical News Sentiment VTRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼1211▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pfizer News argenex News BeOne Medicines News BioNTech News Insmed News Summit Therapeutics News Teva Pharmaceutical Industries News Intra-Cellular Therapies News Genmab A/S News Moderna News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTRS Stock Alerts